Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group
复制标题
DOI:
10.1200/jco.2004.00.7542
复制
发表时间:
2005-10-01
影响因子:
45.3
通讯作者:
Lau, JT
中科院分区:
文献类型:
--
作者:
Lee, AWM;Lau, WH;Lau, JT
Purpose This randomized study compared the results achieved by concurrent chemoradiotherapy (CRT) versus radiotherapy (RT) alone for nasopharyngeal carcinoma (NPC) with advanced nodal disease.Patients and Methods Patients with nonkeratinizing/undifferentiated NPC staged T1-4N2-3MO were randomized to CRT or RT. Both arms were treated with the same RT technique and dose fractionation. The CRT patients were given cisplatin 100 mg/m(2) on days 1, 22, and 43, followed by cisplatin 80 mg/m(2) and fluorouracil 1,000 mg/m(2)/d for 96 hours starting on days 71, 99, and 127.Results From 1999 to January 2004, 348 eligible patients were randomly assigned; the median follow-up was 2.3 years. The two arms were well-balanced in all prognostic factors and RT parameters. The CRT arm achieved significantly higher failure-free survival (72% v 62% at 3-year, P =.027), mostly as a result of an improvement in locoregional control (92% v 82%, P =.005). However, distant control did not improve significantly (76% v 73%, P =.47), and the overall survival rates were almost identical (78% v 78%, P =.97). In addition, the CRT arm had significantly more acute toxicities (84% v 53%, P